

Jing Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4980135/publications.pdf>

Version: 2024-02-01

61
papers

16,457
citations

66343

42
h-index

106344

65
g-index

70
all docs

70
docs citations

70
times ranked

26082
citing authors

#	ARTICLE	IF	CITATIONS
1	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. <i>Cell</i> , 2018, 173, 400-416.e11.	28.9	2,277
2	Oncogenic Signaling Pathways in The Cancer Genome Atlas. <i>Cell</i> , 2018, 173, 321-337.e10.	28.9	2,111
3	<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 822-835.	9.4	1,108
4	Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. <i>Cell</i> , 2017, 170, 1120-1133.e17.	28.9	960
5	An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. <i>Clinical Cancer Research</i> , 2013, 19, 279-290.	7.0	848
6	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. <i>Nature Communications</i> , 2014, 5, 5241.	12.8	780
7	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. <i>Cancer Cell</i> , 2018, 33, 676-689.e3.	16.8	750
8	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. <i>Cell</i> , 2017, 171, 950-965.e28.	28.9	738
9	Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. <i>Cancer Discovery</i> , 2015, 5, 860-877.	9.4	696
10	Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2019, 9, 646-661.	9.4	555
11	Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1. <i>Cancer Discovery</i> , 2012, 2, 798-811.	9.4	432
12	Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. <i>Cancer Cell</i> , 2021, 39, 346-360.e7.	16.8	422
13	A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. <i>Clinical Cancer Research</i> , 2016, 22, 609-620.	7.0	388
14	Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3630-3642.	7.0	353
15	CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. <i>Cancer Discovery</i> , 2018, 8, 1156-1175.	9.4	323
16	Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2386-2394.	1.6	276
17	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , 2018, 23, 194-212.e6.	6.4	245
18	Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. <i>Nature Communications</i> , 2020, 11, 4520.	12.8	218

#	ARTICLE	IF	CITATIONS
19	Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 423-436.	13.2	218
20	Structure-based classification predicts drug response in EGFR-mutant NSCLC. <i>Nature</i> , 2021, 597, 732-737.	27.8	185
21	Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 28575-28587.	1.8	157
22	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. <i>Cancer Cell</i> , 2019, 36, 444-457.e7.	16.8	145
23	The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3638-3647.	1.6	140
24	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. <i>Nature Genetics</i> , 2021, 53, 86-99.	21.4	118
25	Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 6852-6861.	7.0	105
26	A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	101
27	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β -blockers. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	96
28	STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. <i>Journal of Thoracic Oncology</i> , 2020, 15, 777-791.	1.1	94
29	Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2713-2722.	7.0	91
30	Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. <i>Oncotarget</i> , 2017, 8, 73419-73432.	1.8	74
31	The deubiquitinase Otub1 controls the activation of CD8+ T cells and NK cells by regulating IL-15-mediated priming. <i>Nature Immunology</i> , 2019, 20, 879-889.	14.5	68
32	Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4643-4650.	7.0	64
33	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. <i>Nature Communications</i> , 2021, 12, 5086.	12.8	58
34	Metastasis regulation by PPAR δ expression in cancer cells. <i>JCI Insight</i> , 2017, 2, e91419.	5.0	58
35	Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1894-1904.	1.1	57
36	Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. <i>Modern Pathology</i> , 2018, 31, 947-955.	5.5	56

#	ARTICLE	IF	CITATIONS
37	NF- κ B-inducing kinase maintains T cell metabolic fitness in antitumor immunity. <i>Nature Immunology</i> , 2021, 22, 193-204.	14.5	52
38	Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines. <i>Oncotarget</i> , 2017, 8, 86369-86383.	1.8	50
39	An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. <i>Clinical Cancer Research</i> , 2015, 21, 3480-3491.	7.0	48
40	The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. <i>Journal of Clinical Investigation</i> , 2018, 128, 1267-1282.	8.2	48
41	Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-to-mesenchymal transition. <i>BMC Genomics</i> , 2014, 15, 1079.	2.8	45
42	ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	42
43	Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. <i>Nature Communications</i> , 2021, 12, 2606.	12.8	41
44	Multomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. <i>Genome Biology</i> , 2020, 21, 271.	8.8	36
45	PPAR δ and Interferon Gamma Promote Transformation of Gastric Progenitor Cells and Tumorigenesis in Mice. <i>Gastroenterology</i> , 2019, 157, 163-178.	1.3	34
46	Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1821-1839.	1.1	34
47	Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. <i>Nature Medicine</i> , 2022, 28, 557-567.	30.7	26
48	Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPAR γ . <i>Nature Communications</i> , 2022, 13, 2665.	12.8	25
49	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. <i>Nature Communications</i> , 2021, 12, 6655.	12.8	24
50	Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. <i>Oncotarget</i> , 2016, 5, e1234570.	4.6	23
51	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. <i>Nature Communications</i> , 2022, 13, 1797.	12.8	23
52	Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. <i>Oncotarget</i> , 2016, 7, 47998-48010.	1.8	21
53	Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer. <i>Cancer & Metabolism</i> , 2021, 9, 33.	5.0	20
54	The EMT activator ZEB1 accelerates endosomal trafficking to establish a polarity axis in lung adenocarcinoma cells. <i>Nature Communications</i> , 2021, 12, 6354.	12.8	20

#	ARTICLE	IF	CITATIONS
55	Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. <i>Nature Communications</i> , 2021, 12, 6340.	12.8	17
56	SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 4095-4105.	2.8	17
57	Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC. <i>Cancer Research</i> , 2021, 81, 1398-1412.	0.9	16
58	Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 346-357.	7.0	14
59	Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. <i>British Journal of Cancer</i> , 2022, 127, 569-576.	6.4	8
60	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. <i>NAR Cancer</i> , 2022, 4, zcac014.	3.1	7
61	Identification of Transcriptional Heterogeneity and Construction of a Prognostic Model for Melanoma Based on Single-Cell and Bulk Transcriptome Analysis. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	3.7	6